Matrix Capital Management Company, LP
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 13, 2025), Matrix Capital Management Company, LP reported 3 stock positions worth $106.7 million. Its top holding was Maze Therapeutics (MAZE) at 40.2% of the portfolio, followed by Aura Biosciences (AURA, 40.1%) and Zentalis Pharmaceuticals (ZNTL, 19.7%). Compared with Q2 2025, it sold out of 1 and reduced 1. The biggest sale was an exit from Globalfoundries (GFS).
- Most Recent 13F
- Q2 2026
- Location
- Portsmouth, NH
- CIK
- 0001410830
- Portfolio Value
- $106.7M (Q3 2025)
- SEC Filing
- 0001172661-25-004764 ↗ filed Nov 13, 2025
Holdings Value
Holdings 3 stocks · $106.7M
Portfolio Sells Q2 2025 → Q3 2025
Portfolio Buys Q2 2025 → Q3 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 0 | $0 | |
| Q1 2026 | 1 | $46.3M | AURA |
| Q4 2025 | 2 | $57.6M | AURA, MAZE |
| Q3 2025 | 3 | $106.7M | MAZE, AURA, ZNTL |
| Q2 2025 | 4 | $222.8M | GFS, AURA, MAZE, ZNTL |
| Q1 2025 | 4 | $347.2M | GFS, AURA, MAZE, ZNTL |
| Q4 2024 | 5 | $2.2B | ALTR, GFS, PRM, AURA, ZNTL |
| Q3 2024 | 7 | $2.1B | ALTR, GFS, PRM, AURA, ZNTL |
| Q2 2024 | 23 | $13.1B | NVDA, QCOM, TDG, ALTR, MRVL |
| Q1 2024 | 23 | $10.8B | NVDA, TDG, QCOM, ALTR, MRVL |